{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Diphenhydramine+HCl&page=2",
    "query": {
      "intervention": "Diphenhydramine HCl",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 258,
    "total_pages": 26,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Diphenhydramine+HCl&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Diphenhydramine+HCl&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-02T05:26:51.173Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03142165",
      "title": "A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986263 in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Fibrosis"
      ],
      "interventions": [
        {
          "name": "BMS-986263",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Diphenhydramine",
          "type": "DRUG"
        },
        {
          "name": "Famotidine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 33,
      "start_date": "2017-05-11",
      "completion_date": "2017-11-29",
      "has_results": false,
      "last_update_posted_date": "2018-01-12",
      "last_synced_at": "2026-10-02T05:26:51.173Z",
      "location_count": 1,
      "location_summary": "Cypress, California",
      "locations": [
        {
          "city": "Cypress",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03142165"
    },
    {
      "nct_id": "NCT01729494",
      "title": "Belatacept Early Steroid Withdrawal Trial",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Renal Transplantation"
      ],
      "interventions": [
        {
          "name": "Alemtuzumab",
          "type": "DRUG"
        },
        {
          "name": "rabbit antithymocyte globulin",
          "type": "DRUG"
        },
        {
          "name": "Belatacept",
          "type": "DRUG"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "Mycophenolate mofetil",
          "type": "DRUG"
        },
        {
          "name": "early cessation of steroids",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Cincinnati",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 316,
      "start_date": "2012-09",
      "completion_date": "2019-12",
      "has_results": true,
      "last_update_posted_date": "2026-07-24",
      "last_synced_at": "2026-10-02T05:26:51.173Z",
      "location_count": 8,
      "location_summary": "San Francisco, California • Denver, Colorado • Tampa, Florida + 4 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01729494"
    },
    {
      "nct_id": "NCT02541643",
      "title": "Expanded Access Single Named Patient Program With Elotuzumab (BMS-901608) for the Treatment of Patient R-A With Relapsed/Refractory Multiple Myeloma",
      "overall_status": "NO_LONGER_AVAILABLE",
      "study_type": "EXPANDED_ACCESS",
      "phases": [],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Elotuzumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sundar Jagannath",
      "sponsor_class": "OTHER",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2015-09-04",
      "last_synced_at": "2026-10-02T05:26:51.173Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02541643"
    },
    {
      "nct_id": "NCT02474199",
      "title": "Donor Alloantigen Reactive Tregs (darTregs) for Calcineurin Inhibitor (CNI) Reduction",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Liver Transplant Recipient",
        "Living Donor (of the Respective Liver Transplant Recipient)"
      ],
      "interventions": [
        {
          "name": "darTregs",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Acetaminophen",
          "type": "DRUG"
        },
        {
          "name": "Diphenhydramine",
          "type": "DRUG"
        },
        {
          "name": "Immunosuppression (IS) Withdrawal",
          "type": "DRUG"
        },
        {
          "name": "Study Mandated Procedures",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 15,
      "start_date": "2016-06-06",
      "completion_date": "2019-12-16",
      "has_results": true,
      "last_update_posted_date": "2021-02-09",
      "last_synced_at": "2026-10-02T05:26:51.173Z",
      "location_count": 3,
      "location_summary": "San Francisco, California • Chicago, Illinois • Rochester, Minnesota",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02474199"
    },
    {
      "nct_id": "NCT01365052",
      "title": "Safety Trial of Naproxen Sodium/ Diphenhydramine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pain"
      ],
      "interventions": [
        {
          "name": "Naproxen sodium 440 mg/DPH 50 mg (BAY98-7111)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 326,
      "start_date": "2011-05",
      "completion_date": "2011-07",
      "has_results": true,
      "last_update_posted_date": "2015-06-08",
      "last_synced_at": "2026-10-02T05:26:51.173Z",
      "location_count": 19,
      "location_summary": "Chandler, Arizona • Mesa, Arizona • Peoria, Arizona + 16 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Rancho Cucamonga",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01365052"
    },
    {
      "nct_id": "NCT01280591",
      "title": "Evaluate Analgesic/Sedative Efficacy of Naproxen Sodium and Diphenhydramine in Patients With Postsurgical Dental Pain",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pain, Postoperative"
      ],
      "interventions": [
        {
          "name": "Naproxen sodium 440 mg / DPH 50 mg (BAY98-7111)",
          "type": "DRUG"
        },
        {
          "name": "Naproxen sodium 220 mg / DPH 50 mg (BAY98-7111)",
          "type": "DRUG"
        },
        {
          "name": "Naproxen sodium 440 mg (BAYH6689)",
          "type": "DRUG"
        },
        {
          "name": "DPH 50 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "12 Years to 45 Years"
      },
      "enrollment_count": 712,
      "start_date": "2010-10",
      "completion_date": "2011-02",
      "has_results": true,
      "last_update_posted_date": "2015-06-08",
      "last_synced_at": "2026-10-02T05:26:51.173Z",
      "location_count": 2,
      "location_summary": "Austin, Texas • Salt Lake City, Utah",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01280591"
    },
    {
      "nct_id": "NCT01985126",
      "title": "An Efficacy and Safety Study of Daratumumab in Patients With Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor [PI] and Immunomodulatory Drug [IMiD]) or Are Double Refractory to a PI and an IMiD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Daratumumab 16 mg/kg (Part 1)",
          "type": "DRUG"
        },
        {
          "name": "Daratumumab 8 mg/kg (Part 1)",
          "type": "DRUG"
        },
        {
          "name": "Methylprednisolone",
          "type": "DRUG"
        },
        {
          "name": "Acetaminophen",
          "type": "DRUG"
        },
        {
          "name": "Diphenhydramine",
          "type": "DRUG"
        },
        {
          "name": "Daratumumab (Part 2)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 124,
      "start_date": "2013-09-27",
      "completion_date": "2017-05-30",
      "has_results": true,
      "last_update_posted_date": "2018-06-25",
      "last_synced_at": "2026-10-02T05:26:51.173Z",
      "location_count": 15,
      "location_summary": "Duarte, California • Los Angeles, California • Atlanta, Georgia + 12 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01985126"
    },
    {
      "nct_id": "NCT02106325",
      "title": "Ketamine as a Rapidly-Acting Antidepressant in Depressed Emergency Department Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Depression"
      ],
      "interventions": [
        {
          "name": "Ketamine",
          "type": "DRUG"
        },
        {
          "name": "Diphenhydramine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NYU Langone Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 21,
      "start_date": "2013-12",
      "completion_date": "2017-03",
      "has_results": true,
      "last_update_posted_date": "2018-09-14",
      "last_synced_at": "2026-10-02T05:26:51.173Z",
      "location_count": 2,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02106325"
    },
    {
      "nct_id": "NCT02711826",
      "title": "Treg Therapy in Subclinical Inflammation in Kidney Transplantation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Kidney Transplant",
        "Adult Living Donor Kidney Transplant Recipients",
        "Renal Transplant",
        "Living Kidney Donor"
      ],
      "interventions": [
        {
          "name": "Polyclonal Regulatory T Cells",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Everolimus",
          "type": "DRUG"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "Mycophenolate mofetil",
          "type": "DRUG"
        },
        {
          "name": "Mycophenolic acid",
          "type": "DRUG"
        },
        {
          "name": "Acetaminophen",
          "type": "DRUG"
        },
        {
          "name": "Diphenhydramine",
          "type": "DRUG"
        },
        {
          "name": "Biopsy, Kidney",
          "type": "PROCEDURE"
        },
        {
          "name": "Blood Draw",
          "type": "PROCEDURE"
        },
        {
          "name": "Leukapheresis",
          "type": "PROCEDURE"
        },
        {
          "name": "IS regimen conversion",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 32,
      "start_date": "2016-09-20",
      "completion_date": "2023-08-04",
      "has_results": true,
      "last_update_posted_date": "2026-09-24",
      "last_synced_at": "2026-10-02T05:26:51.173Z",
      "location_count": 6,
      "location_summary": "Birmingham, Alabama • San Francisco, California • Aurora, Colorado + 3 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02711826"
    },
    {
      "nct_id": "NCT00076752",
      "title": "Lymphocyte Depletion and Stem Cell Transplantation to Treat Severe Systemic Lupus Erythematosus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lupus Erythematosus, Systemic"
      ],
      "interventions": [
        {
          "name": "fludarabine phosphate",
          "type": "DRUG"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Rituxan (rituximab)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "methylprednisolone",
          "type": "DRUG"
        },
        {
          "name": "immunologic technique",
          "type": "OTHER"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "autologous hematopoietic stem cell transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Diphenhydramine",
          "type": "DRUG"
        },
        {
          "name": "Mesna",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "15 Years to 40 Years"
      },
      "enrollment_count": 9,
      "start_date": "2004-01-30",
      "completion_date": "2013-10-15",
      "has_results": true,
      "last_update_posted_date": "2021-01-05",
      "last_synced_at": "2026-10-02T05:26:51.173Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00076752"
    }
  ]
}